Form 4: Regeneron Director Bonnie L. Bassler Executes Stock Option and Sells Shares Under 10b5-1 Plan

Bonnie L. Bassler, a director at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on August 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 2, 2024, Bonnie L. Bassler, a director of Regeneron Pharmaceuticals, exercised non-qualified stock options to acquire 756 shares of common stock at a price of $371.40.
• Simultaneously, Bassler sold 756 shares of Regeneron common stock at a price of $1,115.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 27, 2024.
• Following these transactions, Bassler directly owns 1,382 shares of Regeneron common stock and holds options for 2,272 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment regarding the company's performance.

Industry Context

Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry, to gauge management's perspective on the company's prospects. Rule 10b5-1 plans are frequently used to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options to align management interests with shareholder value.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings while avoiding potential insider trading concerns.
• Comparing Bassler's transactions to those of other Regeneron executives and peers in similar roles at companies like Amgen (AMGN) or Gilead Sciences (GILD) could provide further context.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The execution of the 10b5-1 plan ensures transparency and avoids potential concerns about insider trading, which is beneficial for stakeholder confidence.

Key Dates